SAN DIEGO, June 3, 2011 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) announced today that it recently met with the Food and Drug Administration (FDA) regarding the New Drug Application ...
What: Shares of Orexigen Therapeutics, a small-cap drug developer focused on treating obesity, slimmed down and lost 25% of its value in May, based on data from S&P Capital IQ, after announcing bad ...
* 48-56 percent of patients lose at least 5 pct of weight * FDA filing planned for first half of 2010 * Stock jumps 24.6 percent (Adds analyst comment, background; updates stock price) By Deena ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results